Onriva Plus Inhalation Capsule 110 mcg+50 mcg is a fixed-dose combination inhalation therapy containing Indacaterol and Glycopyrronium, developed for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This dual bronchodilator formulation is designed to provide comprehensive and sustained airway relaxation, helping patients breathe more easily and maintain better daily lung function.

Indacaterol is a long-acting β₂-adrenergic agonist (LABA), while Glycopyrronium is a long-acting muscarinic antagonist (LAMA). Together, they act through complementary mechanisms to achieve superior bronchodilation compared to monotherapy. Onriva Plus is intended for once-daily use and is suitable for adult patients with COPD, including chronic bronchitis and emphysema.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition and Mechanism of Action

Indacaterol (110 mcg)

Indacaterol works by stimulating β₂-adrenergic receptors in bronchial smooth muscle, leading to prolonged muscle relaxation and airway dilation. It provides rapid onset and sustained bronchodilation for up to 24 hours, improving airflow and reducing breathlessness.

Glycopyrronium (50 mcg)

Glycopyrronium blocks muscarinic receptors in the airways, preventing bronchoconstriction caused by acetylcholine. This anticholinergic action further enhances airway openness and supports long-lasting symptom control.

The combined LABA/LAMA action ensures effective, round-the-clock bronchodilation with a single daily dose.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Benefits

• Provides dual bronchodilation through complementary mechanisms

• Improves lung function and airflow in COPD patients

• Reduces symptoms such as shortness of breath, wheezing, and chest tightness

• Enhances exercise tolerance and daily activity levels

• Once-daily dosing supports better patient adherence

• May help reduce the frequency of COPD exacerbations when used regularly

Indications

Onriva Plus Inhalation Capsule is indicated for the long-term maintenance treatment of airflow obstruction in adult patients with COPD, including chronic bronchitis and emphysema. It is not indicated for the treatment of asthma or for relief of acute bronchospasm.

Dosage and Administration

• For inhalation use only

• One capsule inhaled once daily using a compatible dry powder inhaler

• Capsules must not be swallowed

• Should be taken at the same time each day for optimal control

Proper inhaler technique is essential to ensure effective delivery of the medication to the lungs. Patients should receive clear instructions on device use.

Safety and Precautions

• Not suitable for sudden breathing difficulties or acute COPD attacks

• A short-acting rescue inhaler should be available for emergency use

• Caution is advised in patients with cardiovascular disorders, glaucoma, or urinary retention

• Use only as prescribed by a healthcare professional

Regular monitoring of symptoms and lung function is recommended during long-term therapy.

Storage and Handling

Store Onriva Plus Inhalation Capsules in a cool, dry place, protected from moisture and direct sunlight. Keep out of reach of children. Capsules should remain in the blister pack until immediately before use.